This HTML5 document contains 133 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/
n11http://dx.doi.org/10.1592/

Statements

Subject Item
wd:Q33360104
rdf:type
wikibase:Item
schema:description
article scientifique (publié 2004) teaduslik artikkel 2004年论文 επιστημονικό άρθρο บทความทางวิทยาศาสตร์ artigo científico (publicado na 2004) наукова стаття, опублікована в березні 2004 научная статья vitenskapelig artikkel ২০০৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artículu científicu espublizáu en 2004 2004年論文 article scientific tieteellinen artikkeli bilimsel makale مقالة علمية мақолаи илмӣ artikulong pang-agham 2004年论文 2004年の論文 2004年论文 2004年論文 سائنسی مضمون artigo científico (publicado na 2004) научни чланак mokslinis straipsnis vitskapeleg artikkel מאמר מדעי article científic vědecký článek bài báo khoa học articol științific научна статия tudományos cikk სამეცნიერო სტატია 2004년 논문 artículo científico publicado en 2004 naučni članak 2004年論文 artykuł naukowy 2004年论文 artikull shkencor 2004 nî lūn-bûn artigo científico 2004年论文 vetenskaplig artikel wissenschaftlicher Artikel 2004 թուականի Մարտին հրատարակուած գիտական յօդուած мақолаи илмӣ wetenschappelijk artikel 2004 թվականի մարտին հրատարակված գիտական հոդված scienca artikolo videnskabelig artikel (udgivet 2004) scientific article 2004年論文 2004年论文 مقالهٔ علمی научни чланак articolo scientifico vedecký článok 2004年論文
p:P577
wds:Q33360104-50C6784B-13DF-482F-B50A-09BF9EB2F119
wdt:P577
2004-03-01T00:00:00Z
p:P407
wds:Q33360104-B2960EDB-1431-4DC1-BC0F-8378FBD32030
wdt:P407
wd:Q1860
p:P2860
wds:Q33360104-C41E59D1-8E74-4784-9380-01B8AAFCCDC9 wds:Q33360104-E50F4E7A-A797-4E5C-9647-3EE7ECB5AA24 wds:Q33360104-A4BA8240-0CD1-4AD2-B37A-30751CD6DDE9 wds:Q33360104-AE2865FA-EA1A-4E73-AA8A-11221757A08E wds:Q33360104-9C163608-0A8F-49FE-BB4F-0309519365F9 wds:Q33360104-6808A73D-B8AF-420C-BD05-D860898A707F wds:Q33360104-76454E57-ED73-4B39-9F75-7389F5A32EB5 wds:Q33360104-8111772F-A600-4173-8C16-239B88B1815B wds:Q33360104-8EC73DBA-A878-4342-90CB-A4B41C10CBF9 wds:Q33360104-34B69281-D12E-4559-A32A-24244E63BA97 wds:Q33360104-4155B097-6576-4202-9FC7-B16BD687D6E6 wds:Q33360104-049B9DDB-3B8A-4F08-B27C-58F2C7EF86F3 wds:Q33360104-25D45DBE-869D-43B2-9BDF-12E7069E14AC wds:Q33360104-F5401EA0-8712-4D9C-BB81-9AA6484B5954 wds:Q33360104-FC50BF1A-50EB-42D1-8022-6BE89F5D2402
wdt:P2860
wd:Q33501251 wd:Q33348049 wd:Q31042575 wd:Q33501718 wd:Q33338766 wd:Q33337058 wd:Q33331350 wd:Q33333759 wd:Q33341876 wd:Q34546039 wd:Q33335679 wd:Q33501670 wd:Q33331828 wd:Q33342814 wd:Q33327972
p:P2093
wds:Q33360104-E64062E4-433A-4834-A85E-20DF5C289DE3 wds:Q33360104-F1A91CB9-6A68-49CC-88A4-5593444E459D wds:Q33360104-B1EA3B99-F805-49F0-A8D2-305024C5B357 wds:Q33360104-A0ABEF93-EA25-4D61-8050-F114E8DAC83F
wdt:P2093
David R Williamson Isabelle Boulanger Mariline Tardif Martin Albert
rdfs:label
Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction
skos:prefLabel
Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction
schema:name
Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction
p:P50
wds:Q33360104-AA6D43C4-CD0C-4596-9427-3334391FB3C5
wdt:P50
wd:Q111846736
p:P1476
wds:Q33360104-B24116C1-E5F7-4A6B-9ED2-EA7B6501143F
wdt:P1476
Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction
p:P304
wds:Q33360104-27A1141A-12E3-4682-B2AA-6F6B15ACD060
wdt:P304
409-414
p:P31
wds:Q33360104-43AA22EF-1D11-4218-83A4-66525D357591
wdt:P31
wd:Q13442814
p:P698
wds:Q33360104-9CAE2463-20E6-4E8B-B4F3-D139CE344C32
wdtn:P698
n9:15040656
wdt:P698
15040656
p:P1433
wds:Q33360104-2AC6836B-6541-44CB-9984-CC91FB2CF79E
wdt:P1433
wd:Q7180800
p:P433
wds:Q33360104-58072AD8-5E9A-4594-9EF2-3EEBB9790C60
p:P478
wds:Q33360104-92525980-7A7F-4BD0-AFB3-CD58ED790F16
wdt:P433
3
wdt:P478
24
p:P356
wds:Q33360104-50ADF029-AABC-4FD0-9232-FAABEB5FC5B1
wdtn:P356
n11:PHCO.24.4.409.33168
wdt:P356
10.1592/PHCO.24.4.409.33168